A composition includes a plurality of particulate coated hydrogel microparticles, each of the microparticles including a hydrogel inner core and a particulate shell defined by a plurality of solid nanoparticles, the particulate shell inhibiting aggregation of the microparticles in an aqueous medium and being permeable to allow release of agents from the hydrogel inner core.

The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.

A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH).sub.2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.

Disclosed are controlled release particles including: (a) a core including at least one vitamin which is oil-soluble or oil-dispersible; and (b) a wall at least partially surrounding the core, wherein the controlled release particles are produced by reacting (i) a first composition including a hydrophobic oil, the at least one vitamin, an anti-oxidant and a wax with (ii) a second composition including a water soluble emulsifier, a corn protein and a solvent to form an intermediate product, which is mixed with (iii) a third composition including a cellulosic polymer in water, and dehydrated to provide the controlled release particles. A method for preparing the particles and compositions containing the particles are also disclosed.

The present invention teaches a composition and process for irreversibly agglomerated charge stable core shell microcapsules, each microcapsule containing a benefit agent core material, which may be the same or different, the polymeric all or walls comprising one or more (meth)acrylate polymers, or optionally combinations with other polymers, along with a polyvalent cation. The capsules of the invention adhere better to surfaces, are more stable and are useful for delivery of benefit agents.

The invention provides a particle comprising a lipid core and surface-decorated (nano)particles of at least one stabilizing material, for delivery of active agents.

Therapeutic compliance and more particularly a composition having: a drug substance, selected from an active ingredient and a placebo, and a detection agent. The drug substance being different from the detection agent. The composition being configured such that the detection agent allows to indicate an ingestion of the drug substance. The composition is such that the detection agent includes a hydride that will dissolve upon contact with an aqueous medium in a human or non-human animal body, releasing dihydrogen.

Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.

A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 μm to 20 μm. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.